Sara Nochur - 18 Jan 2024 Form 4 Insider Report for MARINUS PHARMACEUTICALS, INC.

Role
Director
Signature
/s/ Debra A. Mohollen, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
18 Jan 2024
Net transactions value
$0
Form type
4
Filing time
19 Jan 2024, 16:23:49 UTC
Previous filing
25 Sep 2023
Next filing
20 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNS Common Stock Award $0 +4,600 +72% $0.000000 10,950 18 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNS Stock Option (Right to Buy) Award $0 +20,900 $0.000000 20,900 18 Jan 2024 Common Stock 20,900 $9.74 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units (RSUs). The RSUs vest in full on January 18, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.
F2 The option vests and becomes exercisable in 12 equal monthly installments beginning on February 18, 2024, subject to the reporting person's continued service with the Issuer.